V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc

Virology

Volumn 427, Issue 2, 2012, Pages 158-165

  Berro, Reem ^a   Klasse, Per Johan ^a   Moore, John P ^a   Sanders, Rogier W ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

CCR5; CCR5 NT; Drug resistance; Maraviroc; Small molecule CCR5 inhibitors; V3 sequence; Vicriviroc

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GLYCOPROTEIN GP 120; MARAVIROC; VICRIVIROC;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; RESIDUE ANALYSIS; SEQUENCE ANALYSIS; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION; SURFACE CHARGE; VIRUS MUTATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-1; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PIPERAZINES; PROTEIN CONFORMATION; PYRIMIDINES; RECEPTORS, CCR5; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863393752     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.02.006     Document Type: Article

References (41)

1. Anastassopoulou C.G., Marozsan A.J., Matet A., Snyder A.D., Arts E.J., Kuhmann S.E., Moore J.P. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog. 2007, 3:e79.
2. Anastassopoulou C.G., Ketas T.J., Klasse P.J., Moore J.P. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5318-5323.
3. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5698-5703.
4. Baba M., Miyake H., Wang X., Okamoto M., Takashima K. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob. Agents Chemother. 2007, 51:707-715.
5. Berro R., Sanders R.W., Lu M., Klasse P.J., Moore J.P. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009, 5:e1000548.
6. Clevestig P., Pramanik L., Leitner T., Ehrnst A. CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. J. Gen. Virol. 2006, 87:607-612.
7. Cormier E.G., Tran D.N., Yukhayeva L., Olson W.C., Dragic T. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 2001, 75:5541-5549.
8. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., Price D., Stammen B., Wood A., Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49:4721-4732.
9. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., Lin S.W., Ying W., Smith S.O., Sakmar T.P., Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5639-5644.
10. Farzan M., Mirzabekov T., Kolchinsky P., Wyatt R., Cayabyab M., Gerard N.P., Gerard C., Sodroski J., Choe H. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999, 96:667-676.
11. Hill C.M., Deng H., Unutmaz D., Kewalramani V.N., Bastiani L., Gorny M.K., Zolla-Pazner S., Littman D.R. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J. Virol. 1997, 71:6296-6304.
12. Huang C.C., Lam S.N., Acharya P., Tang M., Xiang S.H., Hussan S.S., Stanfield R.L., Robinson J., Sodroski J., Wilson I.A., Wyatt R., Bewley C.A., Kwong P.D. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007, 317:1930-1934.
13. Jakobsen M.R., Roche M., Sterjovski J., Ellett A., Posta F., Lee B., Churchill M.J., Gorry P.R. Characterisation of the virus-cell interactions by HIV-1 subtype C variants from an antiretroviral therapy-naive subject with baseline resistance to the CCR5 inhibitor maraviroc, Program and Abstracts of the Keystone Symposium on HIV Evolution, Genomics and Pathogenesis, poster 248, Whistler 2011.
14. Kuhmann S.E., Pugach P., Kunstman K.J., Taylor J., Stanfield R.L., Snyder A., Strizki J.M., Riley J., Baroudy B.M., Wilson I.A., Korber B.T., Wolinsky S.M., Moore J.P. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 2004, 78:2790-2807.
15. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
16. Laakso M.M., Lee F.H., Haggarty B., Agrawal C., Nolan K.M., Biscone M., Romano J., Jordan A.P., Leslie G.J., Meissner E.G., Su L., Hoxie J.A., Doms R.W. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 2007, 3:e117.
17. Labrecque J., Metz M., Lau G., Darkes M.C., Wong R.S., Bogucki D., Carpenter B., Chen G., Li T., Nan S., Schols D., Bridger G.J., Fricker S.P., Skerlj R.T. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay. Virology 2011, 413:231-243.
18. Lewis M., Simpson P., Delogne C., Sullivan J., Valdez H., Dong W., Woods C., Harrigan R., Westby M. Genotypic analysis of the HIV-1 gp120 V3 loop for treatment-experienced patients enrolled into the MOTIVATE studies and who received maraviroc + optimized background therapy, Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, abstract 539, San Francisco 2010.
19. Marozsan A.J., Kuhmann S.E., Morgan T., Herrera C., Rivera-Troche E., Xu S., Baroudy B.M., Strizki J., Moore J.P. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005, 338:182-199.
20. McNicholas P., Wei Y., Whitcomb J., Greaves W., Black T.A., Tremblay C.L., Strizki J.M. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J. Infect. Dis. 2010, 201:1470-1480.
21. McNicholas P.M., Mann P.A., Wojcik L., Phd P.Q., Lee E., McCarthy M., Shen J., Black T.A., Strizki J.M. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1). J. Acquir. Immune Defic. Syndr. 2011, 56:222-229.
22. Nolan K.M., Del Prete G.Q., Jordan A.P., Haggarty B., Romano J., Leslie G.J., Hoxie J.A. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J. Virol. 2009, 83:3798-3809.
23. Ogert R.A., Wojcik L., Buontempo C., Ba L., Buontempo P., Ralston R., Strizki J., Howe J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373:387-399.
24. Ogert R.A., Ba L., Hou Y., Buontempo C., Qiu P., Duca J., Murgolo N., Buontempo P., Ralston R., Howe J.A. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J. Virol. 2009, 83:12151-12163.
25. Ogert R.A., Hou Y., Ba L., Wojcik L., Qiu P., Murgolo N., Duca J., Dunkle L.M., Ralston R., Howe J.A. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 2010, 400:145-155.
26. Patel M.B., Hoffman N.G., Swanstrom R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J. Virol. 2008, 82:903-916.
27. Pfizer I. Maraviroc Tablets NDA 22-128, Antiviral Drugs Advisory Committee (AVDAC) briefing document 2007.
28. Pugach P., Marozsan A.J., Ketas T.J., Landes E.L., Moore J.P., Kuhmann S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361:212-228.
29. Putcharoen O., Lee S.H., Henrich T.J., Hu Z., Vanichanan J., Coakley E., Greaves W., Gulick R.M., Kuritzkes D.R., Tsibris A.M. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug. J. Virol. 2011, 86:1119-1128.
30. Roche M., Jakobsen M.R., Sterjovski J., Ellett A., Posta F., Lee B., Jubb B., Westby M., Lewin S.R., Ramsland P.A., Churchill M.J., Gorry P.R. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J. Virol. 2011, 85:4330-4342.
31. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., Endres M., Palani A., Shapiro S., Clader J.W., Greenlee W.J., Tagat J.R., McCombie S., Cox K., Fawzi A.B., Chou C.C., Pugliese-Sivo C., Davies L., Moreno M.E., Ho D.D., Trkola A., Stoddart C.A., Moore J.P., Reyes G.R., Baroudy B.M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12718-12723.
32. Strizki J.M., Tremblay C., Xu S., Wojcik L., Wagner N., Gonsiorek W., Hipkin R.W., Chou C.C., Pugliese-Sivo C., Xiao Y., Tagat J.R., Cox K., Priestley T., Sorota S., Huang W., Hirsch M., Reyes G.R., Baroudy B.M. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2005, 49:4911-4919.
33. Tilton J.C., Amrine-Madsen H., Miamidian J.L., Kitrinos K.M., Pfaff J., Demarest J.F., Ray N., Jeffrey J.L., Labranche C.C., Doms R.W. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res. Hum. Retroviruses 2010, 26:13-24.
34. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.
35. Tsamis F., Gavrilov S., Kajumo F., Seibert C., Kuhmann S., Ketas T., Trkola A., Palani A., Clader J.W., Tagat J.R., McCombie S., Baroudy B., Moore J.P., Sakmar T.P., Dragic T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 2003, 77:5201-5208.
36. Tsibris A.M., Sagar M., Gulick R.M., Su Z., Hughes M., Greaves W., Subramanian M., Flexner C., Giguel F., Leopold K.E., Coakley E., Kuritzkes D.R. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 2008, 82:8210-8214.
37. Veazey R.S., Klasse P.J., Ketas T.J., Reeves J.D., Piatak M., Kunstman K., Kuhmann S.E., Marx P.A., Lifson J.D., Dufour J., Mefford M., Pandrea I., Wolinsky S.M., Doms R.W., DeMartino J.A., Siciliano S.J., Lyons K., Springer M.S., Moore J.P. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J. Exp. Med. 2003, 198:1551-1562.
38. Watson C., Jenkinson S., Kazmierski W., Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 2005, 67:1268-1282.
39. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., Dorr P., Ciaramella G., Perros M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 2007, 81:2359-2371.
40. Yuan Y., Maeda Y., Terasawa H., Monde K., Harada S., Yusa K. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. Virology 2011, 413:293-299.
41. Yusa K., Maeda Y., Fujioka A., Monde K., Harada S. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J. Biol. Chem. 2005, 280:30083-30090.